Skip to main content
. 2019 Feb 13;102(4):357–367. doi: 10.1111/ejh.13214

Figure 2.

Figure 2

Outcome of patients receiving haploidentical stem cell transplantation (Haplo‐SCT) with post‐transplant cyclophosphamide (PT‐Cy) and caspofungin as primary antifungal prophylaxis: (A) Kaplan‐Meier estimate of 3‐year overall survival; (B) 1‐year cumulative incidence of non‐relapse mortality; (C) 6‐month cumulative incidence of grade 2‐4 acute GVHD; and (D) 2‐year cumulative incidence of moderate‐severe chronic GVHD